Collectively, these data indicate that patients with advanced NSCLC harboring homozygous SMARCA4 class 1 mutations represent a high‐risk patient population characterized by short overall survival, very low frequency of targetable mutations, and subpar outcomes following response to standard of care therapy with chemotherapeutic regimens or ICI. Here, SMARCA4 is linked to non-small cell lung carcinoma.